Selecting Algorithms for the Efficient Solving of Large Berth Allocation Problems

International audienceIn this presentation, the algorithm selection for the berth allocation problem (BAP) under solution time limits is considered. BAP consists in scheduling ships on berths subject to ready times and ship size constraints, in minimum turnaround time. For the purposes of strategic port capacity planning, BAP must be solved many times in extensive simulations, needed to account for uncertainties on ship traffic, handling times, and also to consider alternative terminal designs. Exact methods exist that solve BAP problems on medium size instances in a few minutes. However, theses methods cannot be adapted to solve many large instances in a short time limit. Even metaheuristics may be too consuming in this setting. The Algorithm Selection Problem (ASP) is the challenge of selecting algorithms with the best overall performance for the considered application. An approach is proposed here to select a portfolio of algorithms, that will each solve the considered BAP instances and return good solutions. The portfolio is built thanks to training instances. The performance is measured by runtime and solution quality. A linear program minimizing the solution quality loss, subject to overall runtime limit, is used to select the portfolio. Thus, the portfolio evolves with changing runtime limits, which is a key design decision in the simulations. For the training and validating datasets, random instances and real ship traffic logs are used. In our experimental study, a portfolio of heuristics is developed which can be used to solve efficiently very large instances of BAP, emerging when time horizons of months or years come into consideration. The evolution of the algorithm portfolios under changing runtime limits as well as their ability to solve new instances are studied

Novel, self-made and cost-ective technique for closed-incision negative pressure wound therapy

Background: It has been suggested that applying the negative pressure wound therapy (NPWT) to a closedsurgical incision may hasten the healing of the incision and decrease the incidence of wound healing complications. The goal of this study is to present the new idea of a simple, self-made, low-cost wound vacuum dressing for closed-incision NPWT that may become an alternative to currently manufactured medicalindustry products.Method: We designed a simple dressing for closed-incision NPWT from gauze pads, polyurethane adhesive film, stoma paste, and a drain tube. Negative pressure was created using a standard 50 ml syringe connected to the drain. First, the dressing was applied to the wound model and on the healthy volunteer. Finally, the dressing was applied to 10 patients after low anterior rectal resection. The vacuum dressing was left in place for 3 days, then changed and placed once more for the next 3 days.Results: We did not observe any adverse effects associatedwith the dressing. All postoperative wounds healed properly. 18 out of 20 dressings were still air-tight 72h post-placement.Conclusions: This simple, self-made dressing for NPWT is safe and effective and may decrease the wound infection rate. However future studies are needed to confirm that hypothesis

European beech stem diameter grows better in mixed than in mono-specific stands at the edge of its distribution in mountain forests

Recent studies show that several tree species are spreading to higher latitudes and elevations due to climate change. European beech, presently dominating from the colline to the subalpine vegetation belt, is already present in upper montane subalpine forests and has a high potential to further advance to higher elevations in European mountain forests, where the temperature is predicted to further increase in the near future. Although essential for adaptive silviculture, it remains unknown whether the upward shift of beech could be assisted when it is mixed with Norway spruce or silver fir compared with mono-specific stands, as the species interactions under such conditions are hardly known. In this study, we posed the general hypotheses that the growth depending on age of European beech in mountain forests was similar in mono-specific and mixed-species stands and remained stable over time and space in the last two centuries. The scrutiny of these hypotheses was based on increment coring of 1240 dominant beech trees in 45 plots in mono-specific stands of beech and in 46 mixed mountain forests. We found that (i) on average, mean tree diameter increased linearly with age. The age trend was linear in both forest types, but the slope of the age–growth relationship was higher in mono-specific than in mixed mountain forests. (ii) Beech growth in mono-specific stands was stronger reduced with increasing elevation than that in mixed-species stands. (iii) Beech growth in mono-specific stands was on average higher than beech growth in mixed stands. However, at elevations > 1200 m, growth of beech in mixed stands was higher than that in mono-specific stands. Differences in the growth patterns among elevation zones are less pronounced now than in the past, in both mono-specific and mixed stands. As the higher and longer persisting growth rates extend the flexibility of suitable ages or size for tree harvest and removal, the longer-lasting growth may be of special relevance for multi-aged silviculture concepts. On top of their function for structure and habitat improvement, the remaining old trees may grow more in mass and value than assumed so far.The authors would like to acknowledge networking support by the COST (European Cooperation in Science and Technology) Action CLIMO (Climate-Smart Forestry in Mountain Regions—CA15226) financially supported by the EU Framework Programme for Research and Innovation HORIZON 2020. This publication is part of a project that has received funding from the European Union’s HORIZON 2020 research and innovation programme under the Marie Skłodowska-Curie Grant Agreement No 778322. Thanks are also due to the European Union for funding the project ‘Mixed species forest management. Lowering risk, increasing resilience (REFORM)’ (# 2816ERA02S under the framework of Sumforest ERA-Net). Further, we would like to thank the Bayerische Staatsforsten (BaySF) for providing the observational plots and to the Bavarian State Ministry of Food, Agriculture, and Forestry for permanent support of the Project W 07 ‘Long-term experimental plots for forest growth and yield research’ (#7831-26625-2017). We also thank the Forest Research Institute, ERTI Sárvár, Hungary, for assistance and for providing observational plots. Furthermore, our work was partially supported by the SRDA via Project No. APVV-16-0325 and APVV-15-0265, the Ministry of Science and Higher Education of the Republic of Poland, the Project “EVA4.0” No. CZ.02.1.01/0.0/0.0/16_019/0000803 funded by OP RDE and the Project J4-1765 funded by the Slovenian Research Agency and also by the Bulgarian National Science Fund (BNSF) and the Project No. DCOST 01/3/19.10.2018

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND). a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Background: Although several disease-modifying treatments are available for relapsing multiple sclerosis, treatment effects have been more modest in progressive multiple sclerosis and have been observed particularly in actively relapsing subgroups or those with lesion activity on imaging. We sought to assess whether natalizumab slows disease progression in secondary progressive multiple sclerosis, independent of relapses. Methods: ASCEND was a phase 3, randomised, double-blind, placebo-controlled trial (part 1) with an optional 2 year open-label extension (part 2). Enrolled patients aged 18–58 years were natalizumab-naive and had secondary progressive multiple sclerosis for 2 years or more, disability progression unrelated to relapses in the previous year, and Expanded Disability Status Scale (EDSS) scores of 3·0–6·5. In part 1, patients from 163 sites in 17 countries were randomly assigned (1:1) to receive 300 mg intravenous natalizumab or placebo every 4 weeks for 2 years. Patients were stratified by site and by EDSS score (3·0–5·5 vs 6·0–6·5). Patients completing part 1 could enrol in part 2, in which all patients received natalizumab every 4 weeks until the end of the study. Throughout both parts, patients and staff were masked to the treatment received in part 1. The primary outcome in part 1 was the proportion of patients with sustained disability progression, assessed by one or more of three measures: the EDSS, Timed 25-Foot Walk (T25FW), and 9-Hole Peg Test (9HPT). The primary outcome in part 2 was the incidence of adverse events and serious adverse events. Efficacy and safety analyses were done in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, number NCT01416181. Findings: Between Sept 13, 2011, and July 16, 2015, 889 patients were randomly assigned (n=440 to the natalizumab group, n=449 to the placebo group). In part 1, 195 (44%) of 439 natalizumab-treated patients and 214 (48%) of 448 placebo-treated patients had confirmed disability progression (odds ratio [OR] 0·86; 95% CI 0·66–1·13; p=0·287). No treatment effect was observed on the EDSS (OR 1·06, 95% CI 0·74–1·53; nominal p=0·753) or the T25FW (0·98, 0·74–1·30; nominal p=0·914) components of the primary outcome. However, natalizumab treatment reduced 9HPT progression (OR 0·56, 95% CI 0·40–0·80; nominal p=0·001). In part 1, 100 (22%) placebo-treated and 90 (20%) natalizumab-treated patients had serious adverse events. In part 2, 291 natalizumab-continuing patients and 274 natalizumab-naive patients received natalizumab (median follow-up 160 weeks [range 108–221]). Serious adverse events occurred in 39 (13%) patients continuing natalizumab and in 24 (9%) patients initiating natalizumab. Two deaths occurred in part 1, neither of which was considered related to study treatment. No progressive multifocal leukoencephalopathy occurred. Interpretation: Natalizumab treatment for secondary progressive multiple sclerosis did not reduce progression on the primary multicomponent disability endpoint in part 1, but it did reduce progression on its upper-limb component. Longer-term trials are needed to assess whether treatment of secondary progressive multiple sclerosis might produce benefits on additional disability components. Funding: Biogen

Scheduling for parallel processing

This book presents scheduling models for parallel processing, problems defined on the grounds of certain scheduling models, and algorithms solving the scheduling problems. The book also provides helpful generalizations about scheduling models. Features of this title are as mentioned below. It introduces the fundamental scheduling concepts. It discusses the technological aspects of scheduling for parallel processing. It presents the notions, concepts, and algorithms that are most immediately applicable in parallel processing. It examines the parallel task model